Retatrutide (sodium salt)

Retatrutide is a triple agonist of the glucagon receptor (GCGR), glucagon-like peptide 1 receptor (GLP-1R), and gastric inhibitory polypeptide receptor (GIP receptor), also known as the glucose-dependent insulinotropic polypeptide receptor.1 It induces cAMP accumulation in HEK293 cells expressing the human GCGR, GLP-1R, or GIP receptor (EC50s = 5.79, 0.775, and 0.0643 nM, respectively). Retatrutide (0.1-30 nmol/kg) decreases plasma glucose levels in an intraperitoneal glucose tolerance test in mice. It decreases body weight, calorie intake, fat mass, and lean mass in a mouse model of diet-induced obesity in a dose-dependent manner. Acute administration of retatrutide (10 nmol/kg) delays gastric emptying and chronic administration for 10 days decreases food intake and body weight in mice.2WARNING This product is not for human or veterinary use.

A GCGR, GLP-1R, and GIP receptor agonist

4731.3

≥98%

Biochemicals/Peptides/Receptor Pharmacology/Agonists

N6-[N-(19-羧基-1-氧代十九烷基)-L-γ-谷氨酰-2-[2-(2-氨基乙氧基)乙氧基]乙酰基]-L-赖氨酰钠盐≥98%

Formal_Name:L-tyrosyl-2-methylalanyl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methyl-L-leucyl-L-leucyl-L-α-aspartyl-L-lysyl-N6-[N-(19-carboxy-1-oxononadecyl)-L-γ-glutamyl-2-[2-(2-aminoethoxy)ethoxy]acetyl]-L-lysyl-L-alanyl-L-glutaminyl-2-methylalanyl-L-alanyl-L-phenylalanyl-L-isoleucyl-L-α-glutamyl-L-tyrosyl-L-leucyl-L-leucyl-L-α-glutamylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide, sodium salt;Synonyms:LY3437943

OC[C@@H](C(N)=O)NC([C@H]1N(C([C@H]2N(C([C@H]3N(C([C@H](C)NC(CNC([C@H](CO)NC([C@H](CO)NC([C@H]4N(C(CN

C221H342N46O68 • XNa

≥ 4 years

Acetonitrile: Slightly soluble DMSO: Sparingly Soluble: 1-10mg/mL PBS (pH 7.2): Sparingly Soluble: 1-10mg/mL Water: Slightly soluble